The plasminogen activation system in periodontal tissue (Review)

Wyganowska-Świątkowska,Marzena; Surdacka,Anna; Skrzypczak-Jankun,Ewa; Jankun,Jerzy

doi:10.3892/ijmm.2014.1653

The plasminogen activation system in periodontal tissue (Review)

Authors:
- Marzena Wyganowska-Świątkowska
- Anna Surdacka
- Ewa Skrzypczak-Jankun
- Jerzy Jankun
View Affiliations

Affiliations: Department of Conservative Dentistry and Periodontology, Poznań University of Medical Sciences, Poznań 60-820, Poland, Urology Research Center, Department of Urology, College of Medicine, University of Toledo, Toledo, OH 43614, USA, Protein Research Chair, Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
Published online on: February 10, 2014 https://doi.org/10.3892/ijmm.2014.1653
Pages: 763-768

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The plasminogen activation system (PAS) plays an essential role in tissue proteolysis in physiological and pathological processes. Periodontitis is a chronic infection associated with increased proteolysis driven by plasminogen activation. In this comprehensive review, we summarise the effects of PAS in wound healing, tissue remodelling, inflammation, bacterial infection, and in the initiation and progression of periodontal disease. Specifically, we discuss the role of plasminogen activators (PAs), including urokinase PA (uPA), tissue-type PA (tPA), PA inhibitor type 1 (PAI-1) and 2 (PAI-2) and activated plasminogen in periodontal tissue, where their concentrations can reach much higher values than those found in other parts of the body. We also discuss whether PA deficiencies can have effects on periodontal tissue. We conclude that in periodontal disease, PAS is unbalanced and equalizing its function can improve the clinical periodontal tissue condition.

View Figures

View References

1	Conese M and Blasi F: The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 8:365–389. 1995. View Article : Google Scholar : PubMed/NCBI
2	Rakic JM, Maillard C, Jost M, et al: Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci. 60:463–473. 2003. View Article : Google Scholar : PubMed/NCBI
3	Slot O, Brünner N, Locht H, Oxholm P and Stephens RW: Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 58:488–492. 1999. View Article : Google Scholar
4	Stoppelli MP, Tacchetti C, Cubellis MV, et al: Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell. 45:675–684. 1986. View Article : Google Scholar : PubMed/NCBI
5	Lijnen HR, Maquoi E, Hansen LB, Van Hoef B, Frederix L and Collen D: Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol. 22:374–379. 2002. View Article : Google Scholar : PubMed/NCBI
6	Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 57:25–40. 2000. View Article : Google Scholar : PubMed/NCBI
7	Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
8	Blasi F: uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today. 18:415–417. 1997. View Article : Google Scholar : PubMed/NCBI
9	Sitrin RG, Todd RF III, Albrecht E and Gyetko MR: The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest. 97:1942–1951. 1996. View Article : Google Scholar : PubMed/NCBI
10	Stefansson S and Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 383:441–443. 1996. View Article : Google Scholar : PubMed/NCBI
11	Ginsburg D, Zeheb R, Yang AY, et al: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. 78:1673–1680. 1986. View Article : Google Scholar : PubMed/NCBI
12	Chorostowska-Wynimko J, Skrzypczak-Jankun E and Jankun J: Plasminogen activator inhibitor type-1: Its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med. 13:759–766. 2004.PubMed/NCBI
13	Stefansson S, McMahon GA, Petitclerc E and Lawrence DA: Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 9:1545–1564. 2003. View Article : Google Scholar : PubMed/NCBI
14	Yamamoto K and Saito H: A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol. 68:371–385. 1998. View Article : Google Scholar : PubMed/NCBI
15	Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2:19–28. 2003. View Article : Google Scholar : PubMed/NCBI
16	Jankun J, Yang J, Zheng H, Han FQ, Al-Senaidy A and Skrzypczak-Jankun E: Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. Int J Mol Med. 29:61–64. 2012.PubMed/NCBI
17	Berkenpas MB, Lawrence DA and Ginsburg D: Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14:2969–2977. 1995.PubMed/NCBI
18	Tucker HM, Mottonen J, Goldsmith EJ and Gerard RD: Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol. 2:442–445. 1995. View Article : Google Scholar : PubMed/NCBI
19	Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 44:139–266. 1985. View Article : Google Scholar : PubMed/NCBI
20	Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep. 8:463–470. 2001.PubMed/NCBI
21	Swiercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH and Jankun J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 6:523–526. 1999.PubMed/NCBI
22	Jankun J, Aleem AM, Selman SH, et al: Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med. 20:683–687. 2007.PubMed/NCBI
23	Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH and Skrzypczak-Jankun E: Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacol Rep. 61:673–680. 2009. View Article : Google Scholar : PubMed/NCBI
24	Klinghofer V, Stewart K, McGonigal T, et al: Species specificity of amidine-based urokinase inhibitors. Biochemistry. 40:9125–9131. 2001. View Article : Google Scholar : PubMed/NCBI
25	Zeslawska E, Jacob U, Schweinitz A, Coombs G, Bode W and Madison E: Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. J Mol Biol. 328:109–118. 2003. View Article : Google Scholar : PubMed/NCBI
26	Zhao G, Yuan C, Wind T, Huang Z, Andreasen PA and Huang M: Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J Struct Biol. 160:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
27	Birn H and Fejerskov O: Fibrynolotic activity of human oral epithelial cells: A preliminary report. Scand J Dent Res. 79:381–386. 1971.PubMed/NCBI
28	Moody GH: The source of plasminogen activator in human saliva. Archs Oral Biol. 27:33–37. 1982.PubMed/NCBI
29	Schmid J, Cohen RL and Chambers DA: Plasminogen activator in human periodontal health and disease. Arch Oral Biol. 36:245–250. 1991. View Article : Google Scholar : PubMed/NCBI
30	Bartold PM, Walsh LJ and Narayanan AS: Molecular and cell biology of the gingiva. Periodontol 2000. 24:28–55. 2000. View Article : Google Scholar
31	Schafer BM, Maier K, Eickhoff U, Todd RF and Kramer MD: Plasminogen activation in healing human wounds. Am J Pathol. 144:1269–1280. 1994.PubMed/NCBI
32	Xiao Y, Li H, Bunn C and Bartold PM: The expression of plasminogen activator system in a rat model of periodontal wound healing. J Periodontol. 72:849–857. 2001. View Article : Google Scholar : PubMed/NCBI
33	Schaefer BM, Maier K, Eickhoff U, Bechtel M and Kramer MD: alpha 2-Antiplasmin and plasminogen activator inhibitors in healing human skin wounds. Arch Dermatol Res. 288:122–128. 1996. View Article : Google Scholar : PubMed/NCBI
34	Thapa B, Kim YH, Kwon HJ and Kim DS: Novel regulatory mechanism and functional implication of plasminogen activator inhibitor-1 (PAI-1) expression in CpG-ODN-stimulated macrophages. Mol Immunol. 49:572–581. 2012. View Article : Google Scholar : PubMed/NCBI
35	Morimoto K, Mishima H, Nishida T and Otori T: Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration. Thromb Haemost. 69:387–391. 1993.PubMed/NCBI
36	Abiko Y, Arai J, Matsuzawa K, Inoue T, Shimono M and Kaku T: Human gingival fibroblast migration promoted by platelet-derived growth factor on titanium is correlated with release of urokinase type plasminogen activator. Bull Tokyo Dent Coll. 37:113–118. 1996.PubMed/NCBI
37	Horowitz JC, Rogers DS, Simon RH, Sisson TH and Thannickal VJ: Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol. 38:78–87. 2008. View Article : Google Scholar : PubMed/NCBI
38	Quigley JP, Gold LI, Schwimmer R and Sullivan LM: Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA. 84:2776–2780. 1987. View Article : Google Scholar : PubMed/NCBI
39	Feghali K and Grenier D: Priming effect of fibronectin fragments on the macrophage inflammatory response: potential contribution to periodontitis. Inflammation. 35:1696–1705. 2012. View Article : Google Scholar : PubMed/NCBI
40	Yee JA, Yan L, Dominguez JC, Allan EH and Martin TJ: Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol. 157:528–534. 1993. View Article : Google Scholar : PubMed/NCBI
41	Allan EH and Martin TJ: The plasminogen activator inhibitor system in bone cell function. Clin Orthop Relat Res. 313:54–63. 1995.PubMed/NCBI
42	Daci E, Everts V, Torrekens S, et al: Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res. 18:1167–1176. 2003. View Article : Google Scholar : PubMed/NCBI
43	Bartold PM: Periodontal tissues in health and disease: introduction. Periodontol 2000. 40:7–10. 2006. View Article : Google Scholar
44	Bartold PM and Narayanan AS: Molecular and cell biology of healthy and diseased periodontal tissues. Periodontol 2000. 40:29–49. 2006. View Article : Google Scholar : PubMed/NCBI
45	Kinnby B, Lecander I, Martinsson G and Astedt BK: Tissue plasminogen activator and placental plasminogen activator inhibitor in human gingival fluid. Fibrinolysis. 5:239–242. 1991. View Article : Google Scholar
46	Kinnby B, Matsson L and Lecander I: The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis. Scand J Dent Res. 102:334–341. 1994.PubMed/NCBI
47	Olofsson A, Lindberg P, Lanke J, Matsson L and Kinnby B: Relationship between fibrinolytic activity and gingival inflammatory reaction in young individuals. J Periodontal Res. 38:104–108. 2003. View Article : Google Scholar : PubMed/NCBI
48	Yin X, Bunn CL and Bartold PM: Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2 (PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients. J Clin Periodontol. 27:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
49	Olofsson A, Matsson L and Kinnby B: Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets. J Periodontal Res. 37:60–65. 2002. View Article : Google Scholar : PubMed/NCBI
50	Kinnby B, Lindberg P, Lecander I and Matsson L: Localisation of plasminogen activator inhibitors in human gingival tissue demonstrated by immunochemistry and in situ hybridization. Arch Oral Biol. 44:1027–1034. 1999. View Article : Google Scholar : PubMed/NCBI
51	Lindberg P, Kinnby B, Lecander I, Lang NP and Matsson L: Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation. Arch Oral Biol. 46:23–31. 2001. View Article : Google Scholar : PubMed/NCBI
52	Papadimitriou S, Tsantarliotou M, Makris G, et al: A clinical study of plasminogen activator activity in gingival tissue in dogs with gingivitis and periodontitis. Res Vet Sci. 80:189–193. 2006. View Article : Google Scholar : PubMed/NCBI
53	Bizzarro S, van der Velden U, ten Heggeler JM, et al: Periodontitis is characterized by elevated PAI-1 activity. J Clin Periodontol. 34:574–580. 2007. View Article : Google Scholar
54	De Taeye B, Smith LH and Vaughan DE: Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol. 5:149–154. 2005.PubMed/NCBI
55	Munford RS: Statins and the acute-phase response. N Engl J Med. 344:2016–2018. 2001. View Article : Google Scholar : PubMed/NCBI
56	Agis H, Bauer M, Knebl G, Watzek G and Gruber R: Effects of platelet-derived growth factor isoforms on plasminogen activation by periodontal ligament and gingival fibroblasts. J Periodontal Res. 43:334–342. 2008. View Article : Google Scholar : PubMed/NCBI
57	Haffajee AD and Socransky SS: Microbial etiological agents of destructive periodontal diseases. Periodontol 2000. 5:78–111. 1994. View Article : Google Scholar : PubMed/NCBI
58	Uitto VJ, Larjava H, Heino J and Sorsa T: A protease of Bacteroides gingivalis degrades cell surface and matrix glycoproteins of cultured gingival fibroblasts and induces secretion of collagenase and plasminogen activator. Infect Immun. 57:213–218. 1989.
59	Oikawa T, Ogura N, Akiba M, Abiko Y, Takiguchi H and Izumi H: Stimulation of plasmin activity in cultured human fibroblast cells by Porphyromonas endodontalis. Int J Biochem. 25:1227–1231. 1993. View Article : Google Scholar : PubMed/NCBI
60	Ogura N, Shibata Y, Matsuda U, et al: Effect of Campylobacter rectus LPS on plasminogen activator-plasmin system in human gingival fibroblast cells. J Periodontal Res. 30:132–140. 1995.
61	Mochan E, Armor L and Sporer R: Interleukin 1 stimulation of plasminogen activator production in cultured gingival fibroblasts. J Periodontal Res. 23:28–32. 1988. View Article : Google Scholar : PubMed/NCBI
62	Sarajlic J, Agis H, Kandler B, Watzek G and Gruber R: Plasminogen activation by fibroblasts from periodontal ligament and gingiva is not directly affected by chemokines in vitro. Arch Oral Biol. 52:663–668. 2007. View Article : Google Scholar : PubMed/NCBI
63	Birkedal-Hansen H: Role of matrix metalloproteinases in human periodontal diseases. J Periodontol. 64:474–484. 1993. View Article : Google Scholar : PubMed/NCBI
64	Johnston KH: Solid and fluid phase assays for bacterial plasminogen activators. J Microbiol Methods. 18:267–274. 1993. View Article : Google Scholar
65	Lottenberg R, Minning-Wenz D and Boyle MD: Capturing host plasmin(ogen): a common mechanism for invasive pathogens? Trends Microbiol. 2:20–24. 1994. View Article : Google Scholar : PubMed/NCBI
66	Pantzar M, Ljungh A and Wadstrom T: Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874. Infect Immun. 66:4976–4980. 1998.PubMed/NCBI
67	Darenfed H, Grenier D and Mayrand D: Acquisition of plasmin activity by Fusobacterium nucleatum subsp nucleatum and potential contribution to tissue destruction during periodontitis. Infect Immun. 67:6439–6444. 1999.PubMed/NCBI
68	Bennett KW and Eley A: Fusobacteria: new taxonomy and related diseases. J Med Microbiol. 39:246–254. 1993. View Article : Google Scholar : PubMed/NCBI
69	Jankun J and Skrzypczak-Jankun E: Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn. 119:410–417. 2009.PubMed/NCBI
70	Largent V, Deneys V, Brichard B, Chantrain C and Vermylen C: Bleeding diathesis in a child with normal screening tests: think about fibrinolysis. Eur J Pediatr. 164:587–588. 2005. View Article : Google Scholar : PubMed/NCBI
71	Mehta R and Shapiro AD: Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 14:1255–1260. 2008. View Article : Google Scholar : PubMed/NCBI
72	Jankun J and Skrzypczak-Jankun E: Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. Exp Ther Med. 1:575–577. 2010. View Article : Google Scholar : PubMed/NCBI
73	Jankun J, Keck R, Selman SH and Skrzypczak-Jankun E: Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. Int J Mol Med. 26:501–504. 2010. View Article : Google Scholar : PubMed/NCBI
74	El-Darouti M, Zayed AA, El-Kamah GY and Mostafa MI: Ligneous conjunctivitis with oral mucous membrane involvement and decreased plasminogen level. Pediatr Dermatol. 26:448–451. 2009. View Article : Google Scholar : PubMed/NCBI
75	Lin Z, Jiang L, Yuan C, et al: Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem. 286:7027–7032. 2011. View Article : Google Scholar : PubMed/NCBI
76	Zeslawska E, Schweinitz A, Karcher A, et al: Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 301:465–475. 2000. View Article : Google Scholar : PubMed/NCBI
77	Brown NJ: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis. 4:315–324. 2010. View Article : Google Scholar : PubMed/NCBI
78	Xue Y, Björquist P, Inghardt T, et al: Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure. 6:627–636. 1998. View Article : Google Scholar
79	Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, et al: Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia. 44:2025–2031. 2001. View Article : Google Scholar : PubMed/NCBI
80	Ritchie CS: Obesity and periodontal disease. Periodontol 2000. 44:154–163. 2007. View Article : Google Scholar
81	Saito T, Shimazaki Y, Koga T, et al: Relationship between periodontitis and hepatic condition in Japanese women. J Int Acad Periodontol. 8:89–95. 2006.PubMed/NCBI
82	Staufenbiel I, Weinspach K, Förster G, et al: Periodontal condition in vegetarians: a clinical study. Eur J Clin Nutr. 67:836–840. 2013. View Article : Google Scholar : PubMed/NCBI
83	Tanaka K, Sasaki S, Murakami K, et al: Relationsip between soy and isoflavone intake and periodontal disesae: the freshmen in dietetic Courses Study II. BMC Public Health. 8:39–46. 2008. View Article : Google Scholar : PubMed/NCBI
84	Smith PC, Santibañez JF, Morales JP and Martinez J: Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin. J Periodont Res. 39:380–387. 2004. View Article : Google Scholar
85	Kushiyama M, Shimazaki Y, Murakami M and Yamashita Y: Relationship between intake of green tea and periodontal disease. J Periodontol. 80:372–377. 2009. View Article : Google Scholar : PubMed/NCBI
86	Pasten C, Olave NC, Zhou L, et al: Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 121:59–65. 2007. View Article : Google Scholar
87	Cho AR, Kim JH, Lee DE, et al: The effect of orally administrated epigallocatechin-3-gallate on ligature-induced periodontitis in rats. J Periodontol. 48:781–789. 2013.PubMed/NCBI
88	Hosokawa Y, Hosokawa I, Shindo S, et al: (−)-Epigallocatechin-3-gallate inhibits CC chemokine ligand 11 production in human gingival fibroblasts. Cell Physiol Biochem. 31:960–967. 2013.
89	Guimarães MR, Coimbra LS, de Aquino SG, et al: Potent anti-inflammatory effects of systemically administrated curcumin modulate periodontal disease in vivo. J Periodontal Res. 46:269–279. 2011.PubMed/NCBI
90	Madhyastha R, Madhyastha H, Nakajima S, et al: Curcumin facilitates fibrynolysis and cellular migration during wound healing by modulation urokinase plasminogen activator expression. Pathophysiol Haemost Thromb. 37:59–66. 2010. View Article : Google Scholar